AMPLATZER AMULET
Device
Abbott Laboratories
Total Payments
$15.2M
Transactions
21,917
Doctors
3,974
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.5M | 8,401 | 2,222 |
| 2023 | $5.8M | 9,321 | 2,119 |
| 2022 | $3.9M | 4,195 | 837 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.8M | 3,456 | 57.6% |
| Consulting Fee | $3.8M | 1,157 | 25.2% |
| Travel and Lodging | $1.6M | 3,964 | 10.8% |
| Food and Beverage | $617,323 | 13,216 | 4.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248,933 | 72 | 1.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $87,413 | 28 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $21,341 | 22 | 0.1% |
| Debt forgiveness | $1,217 | 2 | 0.0% |
Payments by Type
Research
$8.8M
3,456 transactions
General
$6.5M
18,461 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants (CATALYST) | Abbott Laboratories | $1.7M | 0 |
| Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants | Abbott Laboratories | $1.5M | 0 |
| Amplatzer Amulet LAAO vs. NOAC (CATALYST) | Abbott Laboratories | $1.5M | 0 |
| AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | Abbott Laboratories | $926,583 | 0 |
| AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | Abbott Laboratories | $874,164 | 0 |
| Amulet™ ADVANCE LAA | Abbott Laboratories | $861,422 | 0 |
| CATALYST IDE Study | Abbott Laboratories | $443,330 | 0 |
| Amulet ADVANCE LAA | Abbott Laboratories | $282,157 | 0 |
| A Real-World Study to Observe Outcomes of Patients Undergoing Closure with the Amplatzer Amulet Left Atrial Appendage Occluder | Abbott Laboratories | $267,880 | 0 |
| Amulet IDE Study | Abbott Laboratories | $120,450 | 0 |
| Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) | Abbott Laboratories | $96,527 | 0 |
| Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal (TRILUMINATE) | Abbott Laboratories | $93,965 | 0 |
| Abbott Medical - VERITAS Study | Abbott Laboratories | $41,753 | 0 |
| TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR (TRILUMINATE) | Abbott Laboratories | $23,030 | 0 |
| Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS (COAPT) | Abbott Laboratories | $21,441 | 0 |
| A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease (SPIRIT 48) | Abbott Laboratories | $18,370 | 0 |
| VERITAS Study | Abbott Laboratories | $8,515 | 0 |
| Cephea Early Feasibility Study | Abbott Laboratories | $5,780 | 0 |
| Amplatzer Amulet LAAO v NOAC | Abbott Laboratories | $4,895 | 0 |
| AReal-WorldStudytoObserveOutcomesofPatientsUndergoingClosureWiththeAmplatzerAmuletLeftAtrialAppendageOccluder | Abbott Laboratories | $1,225 | 0 |
Top Doctors Receiving Payments for AMPLATZER AMULET
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dayton, OH | $8.9M | 3,493 |
| , M.D., PH.D | Internal Medicine | Bedford, TX | $797,399 | 833 |
| , D.O | Internal Medicine | Lincoln, NE | $547,944 | 384 |
| , MD | Clinical Cardiac Electrophysiology | Lincoln, NE | $504,177 | 481 |
| Atman Shah | Gastroenterology | Chicago, IL | $365,619 | 415 |
| , MD | Interventional Cardiology | Omaha, NE | $289,962 | 271 |
| , M.D | Cardiovascular Disease | San Diego, CA | $166,025 | 127 |
| , M.D | Internal Medicine | Bedford, TX | $164,663 | 174 |
| , MD | Cardiovascular Disease | Winter Park, FL | $153,228 | 239 |
| , MD | Cardiovascular Disease | Kansas City, KS | $142,666 | 110 |
| , M.D | Internal Medicine | Nashville, TN | $136,140 | 265 |
| , M.D | Internal Medicine | Shenandoah, TX | $135,966 | 154 |
| , M.D | Clinical Cardiac Electrophysiology | Phoenix, AZ | $127,416 | 155 |
| , MD | Cardiovascular Disease | Peoria, AZ | $118,034 | 107 |
| , MD | Clinical Cardiac Electrophysiology | Jonesboro, AR | $114,860 | 192 |
| , M.D | Cardiovascular Disease | Omaha, NE | $85,884 | 90 |
| , M.D | Cardiovascular Disease | Nashville, TN | $73,868 | 107 |
| , MD | Pediatrics | Detroit, MI | $71,152 | 51 |
| Rajesh Venkataraman | Internal Medicine | Shenandoah, TX | $59,424 | 95 |
| , MD | Cardiovascular Disease | Charleston, SC | $58,799 | 112 |
| , M.D | Cardiovascular Disease | Miami, FL | $54,238 | 67 |
| , M.D | Interventional Cardiology | Jacksonville, FL | $52,324 | 69 |
| , M.D | Internal Medicine | North Charleston, SC | $46,371 | 93 |
| George Mark | — | Haddon Heights, NJ | $43,373 | 58 |
| , M.D | Cardiovascular Disease | Newark, NJ | $42,726 | 90 |
Ad
Manufacturing Companies
- Abbott Laboratories $15.2M
Product Information
- Type Device
- Total Payments $15.2M
- Total Doctors 3,974
- Transactions 21,917
About AMPLATZER AMULET
AMPLATZER AMULET is a device associated with $15.2M in payments to 3,974 healthcare providers, recorded across 21,917 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $5.5M was paid across 8,401 transactions to 2,222 doctors.
The most common payment nature for AMPLATZER AMULET is "Unspecified" ($8.8M, 57.6% of total).
AMPLATZER AMULET is associated with 20 research studies, including "Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants (CATALYST)" ($1.7M).